Drugs/Medical

Week Adjourned: 9.13.13 – Dialysis Deaths, Auto Worker Severance Pay, Cipro

The week’s top class action lawsuits and settlements including Fresenius Granuflo Dialysis lawsuits, Auto Workers denied severance, and Cipro anti-trust partial settlement.

Top Class Action Lawsuits

Dialysis Death Lawsuit Update. The lawsuits continue against Fresenius Medical Care, the maker of Granuflo and Naturalyte. This week, they found themselves facing a wrongful death class action lawsuit filed by the widow of Earin Blossom. The potential class action, filed in the Northern District of California, alleges the makers of Granuflo and Naturalyte, and their subsidiaries “failed to exercise reasonable care in manufacturing and selling defective dialysis products known as Granuflo and and Naturalyte.”

Tina Nunn, who filed the lawsuit on behalf of herself, her late husband, and those similarly situated, alleges that the dialysates caused fatal complications and sudden death, and caused her husband to incur substantial medical expenses prior to his death.

According to court documents, Earin Blossom began hemodialysis treatments in November 2010. During the course of those treatments, which took place three times a week at a Fresenius dialysis clinic in Fremont, he received both Granuflo and Naturalyte additives. Then, on April 6, 2011, just a few hours after completing a dialysis treatment at the clinic, Blossom suffered a massive heart attack and died.

The lawsuit alleges that Blossom’s metabolic alkalosis, cardiac arrest and subsequent demise were a direct and proximate result of his use of Granuflo and/or Naturalyte. The lawsuit also claims that the defendant knew its products resulted in excess bicarbonate levels in patients, often leading to metabolic alkalosis, a dangerous condition associated with heightened risks for heart attack, cardiac arrhythmia and sudden death.

Both Fresenius Medical Care products—Naturalyte and GranuFlo—are used in the treatment of acute and chronic renal failure during hemodialysis. The concentrate is formulated to be used with a three-stream hemodialysis machine, which is calibrated for acid and bicarbonate concentrates, according to the FDA safety recall initiated in March 2012. The recalled Naturalyte Liquid Acid Concentrate and Naturalyte GranuFlo (powder) Acid Concentrate was manufactured and distributed from January 2008 through June 2012.

An internal memo issued by Fresenius on November 4, 2011 warns that the GranuFlo and NaturaLyte products could lead to a greater risk of cardiac arrest and other heart problems. The memo, which was anonymously leaked to the FDA earlier this year, warned doctors working in Fresenius dialysis centers only that 941 dialysis patients suffered cardiac arrest in 2010 from GranuFlo use. Dangerously high biocarbonate levels would put their patients at a risk of cardiac arrest up to six times higher than that of patients using competing products.

No comment.

Top Settlements

Auto Workers Get $6M. And justice for all…all employees that is—and in this particular case it takes the form a $6 million settlement of a California labor law class action lawsuit alleging discrimination and unfair dismissal. Brought by former employees of Freemont-based New United Motors Manufacturing, Inc. (NUMMI), California’s last auto plant, the lawsuit, alleged that employees who were on disability at the time of the plant closure, were denied the severance benefits.

Specifically, the NUMMI workers’ lawsuit alleged that employees who were on disability in the period between October and the plant’s closure on April 1st did not receive benefits and services offered to employees who were not on disability during that same period. Those benefits and services included a severance package including a base payout with an additional retention bonus determined by years worked at the plant. The plant employees working between October 1st and April 1st were also offered transitional services, including access to a one-stop center, career and educational fairs, and skills assessments.

The plaintiffs also claimed that they, being on leave due to their disabilities and/or NUMMI’s refusal to accommodate their disabilities, were unjustly denied the bonus enhancement and transitional services. Further, the workers alleged in their complaint to the Equal Employment Opportunity Commission (EEOC) that they were physically capable of returning to work during the severance period, but were denied reinstatement. The EEOC issued “right to sue” letters to several NUMMI workers, while retaining the right to continue its investigation.

While the EEOC charges were pending, a group of former employees filed a federal lawsuit in the United States District Court for the Northern District of California. The plaintiffs filed claims for declaratory and injunctive relief, as well as damages for violations of the Americans with Disabilities Act, The Fair Employment and Housing act, the Unfair Business Practices Act, and California’s Public Policies.

The plaintiffs sought reformation of the severance agreement, restitution, lost compensation and other employment benefits and compensatory and punitive damages, and reasonable attorneys’ fees and costs for the defendants’ violations of their rights. Defendants named in the suit included New United Motors Manufacturing, Toyota Motor Corporation and Toyota Motor Sales. A class certification was later granted. Prior to the EEOC’s filing its own lawsuit, the matter was resolved via settlement for $6 million. As a part of the settlement, NUMMI entered into a conciliation agreement with the EEOC.

Floxed But Not Fleeced? Last—but certainly not least—the 900lb gorilla—Bayer—reached a partial settlement in an antitrust class action lawsuit involving the prescription antibiotic Cipro. The lawsuit claims Bayer Corporation, Barr Laboratories, Inc., Hoechst Marion Roussel, Inc., Watson Pharmaceuticals, Inc., and The Rugby Group, Inc. violated antitrust and consumer protection laws by agreeing not to compete with each other, and by keeping lower-cost generic versions of Cipro off the market. This settlement is with Bayer Corporation only; the case against the other manufacturers continues.

FYI—neither the case nor the settlement is about the safety or effectiveness of Cipro. Bayer has paid $74 million into a settlement fund that will compensate consumers and third-party payors (Class Members) who paid or reimbursed for Cipro in California between January 8, 1997 and October 31, 2004. Cipro purchasers not eligible for settlement payments include: (1) anyone who received Cipro through the MediCal Prescription Drug Program, (2) anyone who purchased Cipro to resell it, (3) government entities, (4) the manufacturers and related entities being sued, and (5) all purchasers of Cipro who paid a flat co-payment and who would have paid the same co-payment for a generic version under their health insurance policy.

Individual payments will be based on the total number of valid claims filed and how much the Class Member paid or reimbursed for Cipro. Attorneys’ fees not to exceed one-third of the fund, litigation costs, and other fees and expenses will be deducted prior to distribution. Full details about the settlement can be found in the Settlement Agreement, which is available at www.CiproSettlement.com.

Class Members must submit a claim form by March 31, 2014 in order to get a payment. The claim form and instructions on how to submit, together with complete details of the settlement are available at www.CiproSettlement.com.

Ok Folks, That’s all for this week. Have a good one—see you at the bar!

Week Adjourned: 6.21.13 – Intern Pay, McDonald’s, Flonase

The top class action lawsuits and settlements for the week ending June 21, 2013. Top stories include intern pay, McDonald’s paying workers with plastic, and the much-awaited Flonase settlements.

Top Class Action Lawsuits

Unpaid Interns Going for Big Payday… or at least their day in court. A former unpaid intern at Atlantic Records claims the record company required him to work full-time over eight months without pay, often 10 hours a day, according to a proposed employment class-action law suit filed in State Supreme Court in Manhattan.

Of note, the Atlantic Records class action is the first unpaid internship lawsuit to be filed against a music industry business, according to lawyers involved in lawsuit; the class action alleges that Atlantic Records and its parent, Warner Music Group Corp, violated New York State Labor law by requiring the intern, Justin Henry, of Brooklyn, to work full time without pay.

Henry was an intern in 2007 for Atlantic engaged in filing, faxing, answering phones and fetching lunch for paid employees, according to the suit. He alleges his internship existed solely for the benefit of Atlantic Records, and that he received no training or mentorship. Sadly, we’ve heard this before.

According to the Fair Labor Standards Act and New York Labor Law, unpaid internships must exist for training purposes and employers may derive “no immediate advantage” from the work provided by interns.

So, Henry is seeking to recover unpaid minimum wages ($7.15 per hour) and overtime, as well as attorney’s fees.

Plastic Pay at McDonald’s? No stranger to employment lawsuits, McDonald’s is facing a potential employment class action, with a new twist. The lawsuit was filed by an employee in Pennsylvania who alleges she was issued with a fee-loaded Chase Bank Debit card, instead of a paycheck. Yes, really.

Natalie Gunshannon, a 27-year old single mother, worked at McDonalds in Luzerne County, PA, at an hourly rate of $7.44 from April 24 through May 15. When she received her first paycheck, it was not a check at all but rather a JP Morgan Chase debit card which would cost her $1.50 for ATM withdrawals, $5 for over-the-counter cash withdrawals, $1 per balance inquiry, 75 cents per online bill payment, and $15 for a lost or stolen card. Nice. I wonder who thought this one up.

When Gunshannon asked if she could be paid by check she was allegedly told that the debit card was the only option. Furthermore, her future earnings would be deposited into the debit card account and she could access her money from there. “McDonald’s does not provide a choice for hourly employees to receive their justly earned wages through a bank check, cash or direct deposit,” the lawsuit said. Pennsylvania law states that employees are entitled to have a choice to be paid by check or cash.

Go get’em!

Top Settlements

Flonase Settlements Approved. GSK will have to pony up $185 million in two recently approved settlements involving the marketing—or not—of Flonase nasal spray. They were facing two antitrust class actions both of which allege that GSK deliberately prevented generic versions of Flonase nasal spray from going to market.

The Flonase settlements total $185 million, with $150 million designated for reimbursement to people and entities in the US who purchased Flonase directly from GSK at any time from May 19, 2004 until March 6, 2006. For complete information on this settlement, and to download forms, visit flonasedirectsettlement.com The case is, In re Flonase Antitrust Litigation, No. 08-CV-3149, is pending in the United States District Court for the Eastern District of Pennsylvania.

A second class involving those who indirectly purchased Flonase and generic Flonase—will receive reimbursement from a $35 million settlement fund. These class members include anyone who purchased Flonase or generic Flonase for personal, family or household consumption in the United States and its territories from May 18, 2004 through March 31, 2009. Also included in the class is anyone who made co-payments or other partial out-of-pocket payments through their health plans. For complete information on this settlement visit flonasesettlement.com The case is In re Flonase Antitrust Litigation, Case No. 8-cv-3301 and Medical Mutual of Ohio v. GSK, Case No. 12-cv-4212 in the Eastern District of Pennsylvania.

Okee dokee—that’s it for this week. A safe and happy weekend to all. See you at the bar!

Week Adjourned: 6.7.13 – Crest Toothpaste, Organic Seed Mix, Lipitor

Organic Seed Mix, Lipitor, and Crest Toothpaste top our Week Adjourned wrap of top class action lawsuits and settlements for the week ending June 7, 2013

Top Class Action Lawsuits

Going Organic Leads to Going to Hospital? Heads-up anyone who bought Townsend Farms Organic Anti-Oxidant Blend frozen berry and pomegranate seed mix: A woman who alleges she fell ill with a hepatitis A infection and was hospitalized after eating this product has filed a lawsuit against Oregon-based Townsend Farms.

According to the food poisoning lawsuit, plaintiff Karen Echard purchased and consumed Townsend Farms Organic Anti-Oxidant Blend in the Phoenix area in April of 2013. Attorneys allege that she fell ill with symptoms of hepatitis A infection, including fever, chills, nausea, abdominal pains and jaundice during an illness that started on May 21.

The Organic Frozen Berry Seed Mix class action states that Karen sought medical treatment for her illness on more than one occasion and was hospitalized for 5 days. Her attorneys allege that Karen, a healthcare practitioner and student, fears she will lose her job and be forced to discontinue her schoolwork due to her illness, as she continues to experience the effects of her hepatitis A infection. The Townsend Farms lawsuit asks for damages including physical injury, medical and medical-related expenses, wage and lost earning capacity damages.

On June 6, the Centers for Disease Control and Prevention announced that at least 61 people from 7 states had fallen ill with hepatitis A infections in a “Multistate outbreak of Hepatitis A infections potentially associated with ‘Townsend Farms Organic Anti-Oxidant Blend’ frozen berry and pomegranate mix.”

Lipitor Diabetes Link Looking at Lawsuit. Lipitor is making news—this time it all about what the anti-cholesterol drug shouldn’t be doing—allegedly. Pfizer, the maker of Lipitor (atorvastatin) is facing a mounting number of these personal injury lawsuits, alleging the drug causes diabetes. In fact, several of the initial Lipitor diabetes lawsuits have just been green lit for a Multi-district litigation—or MDL.

The Lipitor lawsuits allege that Pfizer has failed to adequately warn consumers of the risk for developing diabetes associated with the statin. In 2012 Pfizer updated the Lipitor labeling to include warnings of increased risk for diabetes, however, the lawsuits contend that this was insufficient.

Lipitor belongs to a class of drugs called statins, which are used to lower cholesterol by reducing blood levels of low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, a contributing factor in heart disease. A study (Culver AL, Ockene IS, Balasubramanian R, et al. “Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative.” Archives of Internal Medicine, 2012,172(2): pp.144-152.), completed in 2012, as part of the Women’s Health Initiative (WHI) found an association between the statin class of medications and the development of type 2 diabetes in women, particularly post-menopausal women.

Among the most recent Lipitor diabetes lawsuits filed is that of Margaret Clark, filed in the US District of South Carolina, this April. She contends she was prescribed Lipitor in 2002 to address her risk for heart disease. At the time, according to her lawsuit, she was considered a healthy weight. However, in February 2012, Clark was diagnosed with type 2 diabetes.

Clark’s lawsuit alleges Pfizer knew or should have known that there was a connection between Lipitor and diabetes before it was made publically available in 1997. Instead, the warning was only added to the product labeling in February 2012, after the FDA’s Division of Metabolism and Endocrinology Products requested that a warning be provided for consumers and the medical community.

According to the lawsuit, the warning did not actually mention type 2 diabetes, but rather stated “Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.”

The Lipitor lawsuit also states “Until the February 2012 label change, Lipitor’s label never warned patients of any potential relation between changes in blood sugar levels and taking Lipitor.” And, “Despite the February 2012 label change, Lipitor’s label continues to fail to warn consumers of the serious risk of developing type 2 diabetes per se when using Lipitor.”

Top Settlements

Crest Toothpaste, er, Crestfallen? A preliminary settlement has been reached in the consumer fraud class action lawsuit pending against Procter & Gamble Co (P&G). The lawsuit alleges the company falsely advertised the benefits of its Crest Sensitivity Treatment & Protection toothpaste. Specifically, the Crest lawsuit, entitled, Edward Rossi v. The Procter & Gamble Co., Case No. 11-07238 (JLL) (MAH), U.S. District Court, District of New Jersey, claims P&G engaged in misleading and deceptive advertising and marketing of its Crest Sensitivity Toothpaste.

The tentative Crest toothpaste settlement, if approved, could include anyone in the US who purchased Crest Sensitivity Treatment & Protection toothpaste between February 2011 and March 2013. If you purchased this toothpaste between those dates, you may be eligible to claim a full or partial refund from the settlement. If approved, potential class members must submit a valid claim form and proof of purchase in order to receive damages. Class members with with proof of purchase will be able to claim a full refund of the purchase price they paid. Those without documentation will receive a refund of $4. Only one tube of Crest Sensitivity toothpaste will be refunded.

Valid claim forms and any supporting documents must be postmarked no later than August 19, 2013. Detailed claims filing instructions are provided below.

A Final Fairness Hearing will be held on September 12, 2013.

For complete details on filing a claim, and to download forms, visit: http://www.sensitivitytoothpastesettlement.com

Okee dokee—that’s it for this week—happy and safe weekend to you all—see you at the bar!

Week Adjourned: 10.19.12 – Healthcare Workers, Madden NFL, Chantix

The weekly wrap on top class action lawsuits and settlements for the week ending October 19, 2012. This week’s top stories include Healthcare workers at Maxim Healthcare, Electronic Arts and NFL Madden games and the first Chantix settlement.

Top Class Action Lawsuits

Overworked and Underpaid on Overtime. An overtime class action lawsuit has been filed against Maxim Healthcare Services Inc, by Jas

mine Lawrence, who was employed as a Home Health Aide by the defendant until October 2012.

In the unpaid overtime lawsuit, Lawrence alleges that Maxim Healthcare Services Inc, violated, and continues to violate, the Ohio Minimum Fair Wage Standards Act (OMFWSA) because of its willful failure to compensate her and the class members at a rate not less than one and one-half times the regular rate of pay for work performed in excess of 40 hours in a workweek. Lawrence claims she regularly worked over 70 hours per week while employed by Maxim Healthcare and the majority of her time was spent performing general housekeeping duties as opposed to patient care.

Lawrence also alleges that she and the members of the putative class who are employed by the Defendant in Ohio are “employees” within the meaning of the OMFWSA.

Lawrence, the lead plaintiff in the employment class action, seeks to bring her claim for violation of the Fair labor Standards Act (FLSA) as a nation-wide collective action, and as a statewide class action based for violation of the OMFWSA.

Maxim Healthcare Services, Inc, is a Maryland corporation which, through hundreds of office locations nationwide, provides in-home personal care, management and/or treatment of a variety of conditions by nurses, therapists, medical social workers, and home health aides. Lawrence and the class are represented by Ben Stewart of Stewart Law PLLC.

Top Settlements

And it’s a Touchdown! The Plaintiffs score a proposed $27 million settlement that’s been reached in a class action lawsuit pending against Electronic Arts. The Electronic Arts settlement, if approved, will apply to anyone who purchased a new copy of an EA Madden NFL, NCAA Football or Arena Football video game between 2005 and 2012 and is an eligible class member.

The backstory—in case you missed it—The Electronic Arts video game antitrust lawsuit was filed in 2008 entitled Pecover v. Electronic Arts, Inc., and alleged that EA violated antitrust and consumer protection lawsuits by holding exclusive license agreements with the NFL, NCAA and AFL to market branded football software. The lawsuit further alleged that the arrangement shut out competitors, enabling EA to charge 70 percent more for “Madden NFL.”

And the skinny on the proposed deal: Class Members of the EA football game class action settlement include all U.S. consumers who bought a new copy of an Electronic Arts’ Madden NFL, NCAA Football, or Arena Football video game for Xbox, Xbox 360, PlayStation 2, PlayStation 3, GameCube, PC, or Wii, with a release date of January 1, 2005 to June 21, 2012.

If approved by the court at the February 7, 2013 Final Fairness Hearing, Settlement Class Members who submit timely and valid claim forms will receive the following CASH benefits:

If you are an eligible Settlement Class Member, your share of the net proceeds of the Settlement will be based upon the number of video game titles you purchased new, as well as the number of Settlement Class Members who submit valid claims.

Valid claims for the purchase of Madden NFL, NCAA Football, or Arena Football video games for the Xbox, PlayStation 2, PC, or GameCube platforms (“Sixth Generation Purchasers”) will be valued at $6.79 per new game purchased, up to a total of eight units ($54.32).

Valid claims for the purchase of Madden NFL, NCAA Football, or Arena Football video games for the Xbox 360, PlayStation 3, or Wii platforms (“Seventh Generation Purchasers”) will be valued at $1.95 per new game purchased, up to a total of eight units ($15.60).

The only way to receive cash benefits from the EA antitrust settlement is to submit a Claim Form either online at EASportsLitigation.com or postmarked no later than March 5, 2013.

Let’s hope this settlement levels the playing field…

Here’s a Bittersweet Ending… A settlement has been reached in a lawsuit against Pfizer and its anti-smoking drug Chantix. The Pfizer Chantix settlement, the details of which remain confidential, was reached just prior to the case going to trial.

The lawsuit was brought by the widow of Mark Alan Whitely, from Minnesota, who allegedly killed himself in November 2007 as a result of taking the controversial drug. The lawsuit alleged that Pfizer failed to sufficiently warn that Chantix could increase the risk of suicide.

FYI—in July 2009, the FDA announced an update to Chantix (known generically as varenicline) warnings, alerting patients to the risk of serious mental health events linked to use of the smoking cessation drug. Pfizer, maker of Chantix, was required to put a Boxed Warning on the Chantix label, highlighting the risk of depressed mood, hostility and suicidal thoughts when using the medication. When the FDA made its announcement in 2009, it had received 98 crude reports of completed suicide associated with Chantix (a crude report means the FDA had not examined each report in depth to ensure there were no duplicates). It had a further 188 crude reports of suicide attempts.

The Whitely lawsuit is reportedly the first of some 2,500 Chantix cases that have been combined in a multidistrict litigation (MDL) in Alabama for pretrial evidence-gathering and the first trials.

The consolidated cases are In re Chantix (Varenicline) Products Liability Litigation MDL 2092, 09-cv-2039 U.S. District Court, Northern District of Alabama (Florence). The consolidated cases are In re Chantix (Varenicline) Products Liability Litigation MDL 2092, 09-cv-2039 U.S. District Court, Northern District of Alabama (Florence).

And on that note—I’ll see you at the bar. Have a great weekend!

Week Adjourned: 2.24.12

The weekly wrap of top class action lawsuits and lawsuit settlements for the week ending February 24, 2012.

Top Class Actions

Hotels.com—too good to be true? Kaylen Silverberg thinks so. She filed a consumer fraud class action lawsuit this week against the online booking agency, alleging it does not back up its promise to refund money if hotel guests can find a better rate elsewhere online.

Instead, Silverberg’s lawsuit claims, Hotels.com sets an “arbitrary and undisclosed limit” on refunds.

Silverberg’s lawsuit states Hotels.com will not back up its promise: “‘after you book with Hotels.com, if you find a lower publicly available rate on line for the same dates, hotel, and room category, we will match the price and refund you the difference.'” Instead, the lawsuit states, “Hotels.com has an arbitrary and undisclosed policy to refund only a portion of the difference between its rate and other, lower rates. For example, in Silverberg’s case, Hotels.com stated that ‘we can only refund you $142,’ even though the price difference was substantially greater.”

Silverberg’s story, short version, is allegedly that she booked a room through Hotels.com for two nights in Rancho Palos Verdes, CA., for $355 per night, then found a $223 rate at HotelClub.com. A third website advertised an even lower rate, $213. Silverberg then asked Hotels.com to back up its guarantee but she was told by the company that they would refund her only $71 a night, which she calls “an arbitrary and undisclosed limit.”

The lawsuit seeks restitution and class damages for breach of contract and unjust enrichment—otherwise known as “business as usual.”

Top Settlements

Every so often a class action settlement comes along that results directly from very unfortunate circumstances. This is one such settlement. This week, Teva Pharmaceuticals, the maker of Propofol, announced it will settle 120 personal injury lawsuits arising from a hepatitis C outbreak in Southern Nevada. The amount of the Nevada Propofol settlement is a reported $285 million.

The Israeli-based generic drug maker was facing lawsuits brought by some 150 former patients of The Endoscopy Center of Southern Nevada and its sister clinics, who contracted the disease after receiving propofol at the clinics. LAS reported on this in some detail at the time.

According to a report in the Las Vegas Review Journal, nine hepatitis C cases were found to be linked to the clinics which were run by Dr. Dipak Desai. Seven of the nine cases were genetically linked to the center. Health officials called another 106 cases “possibly linked.” According to health officials, more than 60,000 former clinic patients were potentially exposed to hepatitis C because of unsafe injection practices by nurse anesthetists at the clinics.

Teva lost the first three trials and was facing payments of nearly $800 million dollars in compensatory and punitive damages. The fourth trial was under way when settlement talks began in earnest. The settlement leaves 15 lawsuits unresolved.

Antennagate may be drawing to a close…if a preliminary settlement reached in a defective products class-action lawsuit against Apple is approved. The lawsuit alleges underperformance of its iPhone 4 resulting from antenna problems. And oh brother did we ever hear about it! While the iPhone 4 settlement per class member is certainly not large, by anyone’s measure—the size of the class certainly is—25 million US residents no less, each of whom could receive $15 in cash or a bumper case provided by Apple under the terms of the settlement. So, don’t be quitting your day job just yet.

The class action combined 18 separate lawsuits, all of which allege Apple was “misrepresenting and concealing material information in the marketing, advertising, sale, and servicing of its iPhone 4—particularly as it relates to the quality of the mobile phone antenna and reception and related software.”

As part of the iPhone 4 settlement original purchasers will be sent emails before April 30, 2012 alerting them to the settlement. The claims period is then open for 120 days.

OK—And it’s off to the bar we go. See you there!

Week Adjourned: 12.9.11

A wrap-up of the week’s top class action lawsuits and lawsuit settlements, for the week ending December 9, 2011.

Top Class Actions

Seems Green Mountain may have been Roasting More Than Coffee. The company got hit with a securities class action lawsuit this week alleging it has been cooking the books.

The class action is brought against GMCR, certain of its officers and directors, and the underwriters of the Offering for violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. GMCR, based in Waterbury, Vermont, is a leader in the specialty coffee and coffee maker businesses.

FYI—GMCR produces coffee, tea and hot cocoa from its family of brands, including Tully’s Coffee(R), and manufactures the popular Keurig single-cup brewing systems that use “K-Cup” portion packs.

The lawsuit alleges that, during the Class Period, certain defendants systematically and strategically manipulated GMCR’s revenues. To do so, defendants used one of GMCR’s key fulfillment vendors, M. Block & Sons (“MBlock”), as a captive warehouse to harbor expired, excessively manufactured, or otherwise unsold product. Pursuant to the fraudulent scheme, GMCR improperly booked revenues associated with falsified sales orders for hundreds of millions of dollars in K-Cup and Keurig Brewer products, which resulted in the material overstatement of the Company’s profits, inventory, and product demand levels. GMCR also fraudulently overstated its assets in proportion to its fictitious revenues by carrying the proceeds of phantom sales as assets on its balance sheet throughout the Class Period.

On October 17, 2011, David Einhorn, a prominent activist investor, released a comprehensive report, including witness testimonials by former GMCR and MBlock employees, disclosing GMCR’s misconduct and questionable relationship with MBlock. Following the release of the report, the price of GMCR shares fell approximately 10% from its closing price of $92.09 on October 14, 2011 to close at $82.50 on October 17, 2011, the next trading day, on unusually heavy trading volume.

On October 19, 2011, after Einhorn’s presentation was more widely distributed, the price of GMCR common stock fell another 15% to close at $69.80 on October 19, 2011, on unusually heavy trading volume.

Finally, on November 9, 2011, GMCR announced disappointing earnings results and skyrocketing inventory. On this news, GMCR shares dropped 40%, from a close of $67.02 on November 9 to a close of $40.89 on November 10, 2011, on extremely heavy trading volume.

The securities lawsuit has been brought on behalf of purchasers of the common stock of Green Mountain Coffee Roasters, Inc. (“GMCR” or the “Company”) between February 2, 2011 and November 9, 2011, inclusive (the “Class Period”), including purchasers of GMCR’s common stock pursuant and/or traceable to the Company’s public offering on or around May 5, 2011 (the “Offering”).

Top Settlements

HRT Breast Cancer Settlement. This one was all over the news this week. Three women who filed lawsuits against Wyeth Pharmaceuticals and Pharmacia Upjohn alleging that their diagnoses of breast cancer were directly attributable to their use of Hormone Replacement Therapy (HRT) drugs, were awarded $72.6 million by a jury in Philadelphia hearing their consolidated lawsuit. The jury awarded $20 million to Ms. Elfont, $27.85 million to Ms. Kalenkoski and $24.75 million to Ms. Mulderig, according to the plaintiffs’ attorneys.

The three women filed individual lawsuits in July 2004 against Wyeth Pharmaceuticals and Pharmacia Upjohn, both of which have since been acquired by Pfizer.

The back story, in brief, is that Elfont, 66, had taken hormone therapy drugs for over two years before being diagnosed with breast cancer in 1997. Sixty-eight year old Kalenkoski was diagnosed with breast cancer in 2002, having taken Prempro for over four years, while Mulderig, also 68, took Premarin and Provera for 11 years before she received her breast cancer diagnosis, the PennRecord reported. It’s tragic and shocking.

According to a Bloomberg News report, Pfizer’s Wyeth and Upjohn units have lost 10 out of the 18 hormone therapy cases against them in civil court trials since 2006. Earlier this year Pfizer announced it had settled a third of the pending Prempro cases, it had set aside $772 for related claims, Bloomberg reported.

Another Bank Biggie this Week… Bank of America (BofA) agreed a $315 million settlement in a securities fraud class action lawsuit that alleged the bank was misled about mortgage-backed investments sold by its Merrill Lynch unit. The settlement needs court approval in order to fly–and guess who’s making that decision? US District Judge Jed Rakoff–so all bets are off that this one get’s approved…

The Public Employees’ Retirement System of Mississippi pension fund led the lawsuit, alleging that the investments contained questionable subprime mortgages written by lenders Countrywide Financial Corp., First Franklin Financial, and IndyMac Bancorp – IndyMac went under in 2008.

Ok – That’s enough for this week. See you at the bar.

Week Adjourned: 11.4.11

Week Adjourned: the weekly wrap of class action lawsuits and settlements, November 4, 2011

Top Class Actions

Could this mean resolution for thalidomide victims?…New research suggests that thalidomide—a drug that caused thousands of horrific cases of deformities in children—caused far more deformities in the U.S. than were reported during the height of the pharmaceutical crisis of the early 1960s.

Invented by German drug company Grunenthal, thalidomide was widely used throughout Europe during the late 1950s and early 1960s, resulting in thousands of deaths and extreme, disfiguring birth defects when used by women during pregnancy. The drug was never approved in the United States, but the new lawsuit filed late October 2011 alleges that as many as 2.5 million doses of the drug were distributed by more than 1,200 doctors to more than 20,000 people, including pregnant women.

Newly discovered and translated documents reveal that Smith, Kline and French (SKF), now owned by GlaxoSmithKline (GSK)conducted a trial of the drug in 1956 and 1957, but buried the evidence, allegedly resulting in a missed opportunity to save thousands of lives.

Instead, according to the filed lawsuit, brought on behalf of 13 men and women with severe birth defects, SKF concealed the results of its trial from the public, allowing another company, Richardson-Merrell, now owned by Sanofi-Aventis to move ahead with large-scale “clinical trials” that involved more than 20,000 people, including pregnant women.

The lawsuit also claims that conclusions made in the early 1960s about the types of birth defects caused by the thalidomide were incorrect.

According to legal counsel, researchers concluded that thalidomide causes bilateral birth defects, such as two missing or shortened arms or hearing loss in both ears. As a result, babies born with unilateral defects, such as one deformed limb, or hearing loss in only one ear were not deemed thalidomide victims, even when their mothers were given the drug while pregnant.

However, new research involving thalidomide as part of a treatment regimen in cancer patients show that many of the assumptions used in the 1960s are incorrect. The thalidomide lawsuit alleges that this new understanding of the drug means that many individuals who experienced unilateral defects may have been misdiagnosed when their doctors told them thalidomide could not have been the cause.

“Among other things we intend to show in court that thalidomide does not work through a neural mechanism as previously thought, but affects the vascular system,” a lawyer for the plaintiffs said.

The complaint claims that the defendants are either guilty of or liable for a civil conspiracy, failing to report and covering up evidence that thalidomide was harmful, especially when taken during the early stages of pregnancy. The lawsuit also says that the defendants were negligent in continuing to manufacture, test and distribute the drug.

Top Settlements

Motrin SJS Verdict. This is one for the books. Let’s hope it makes a difference. On October 3, 2011, a Los Angeles jury returned a record-setting verdict against Johnson & Johnson and their fully owned subsidiary McNeil Consumer Healthcare for $48.2 million—with pre-interest and cost of judgment it’s expected to reach $60 million. The lawsuit alleged that Motrin caused SJS/TENS or Stevens Johnson Syndrome (SJS), also known as Erythema Multiforme, Leyll’s Syndrome, and in its later stages, Toxic Epidermal Necrolysis (TEN). SJS/TEN is a serious and potentially life-threatening disease that causes large areas of the skin to become detached and lesions to develop in the mucous membranes.

The verdict was based on findings of malice towards the consumers of the over-the-counter drug Motrin, specifically for not putting a warning label on the product that could have spared Trejo’s and others’ health. This is believed to be the first verdict of its kind involving punitive damages associated with this over-the-counter temporary pain reliever.

At age 16, Christopher Trejo, who is now 22 years old, took some Motrin as directed on the label for less than one week, but contracted TEN. It caused a severe inside-out exfoliating reaction affecting all of his mucosal membranes, which is equivalent to second- and third-degree burns over 100% of his body. The TEN reaction also caused severe pulmonary damage, near-blindness, infertility, whole-body scarring and a hypoxic brain injury. Trejo’s abilities to see, hear, smell, taste and touch have been severely diminished.

After hearing the evidence, the jury found that the labeling on Motrin was inadequate and should have been changed years earlier to properly educate and alert consumers to the developing signs of severe reactions, which include skin reddening, rash and blisters. Early detection and treatment of these symptoms can prevent TEN or SJS.

Apple Playing the Same Old tune? Apple, Inc., has agreed to settle a consumer fraud class action lawsuit that could amount to over $50 million dollars in payouts—but before you get all excited know this “Apple has agreed to provide an iTunes® Store credit in the amount of $3.25 to all settlement class members who qualify and submit a valid claim form. ” That’s the skinny.

The lawsuit claimed that Apple advertised and sold gift cards which stated that if one purchased and used the gift card, all songs purchased at Apple’s online iTunes® Store would cost 99¢ per song. The lawsuit further claimed that in April, 2009, Apple raised the price of certain songs at the iTunes® store, yet refused to honor the promised 99¢ price when the gift cards were redeemed. In addition, the company continued to sell iTunes® gift cards with the phrase, “Songs are 99¢” printed on them.

Consumers who were overcharged for iTunes songs while using iTunes® 99¢ gift cards are now eligible to receive an iTunes® Store credit in the amount of $3.25 after completing the simple iTunes® class action lawsuit online claim form. Millions of e-mails are currently being sent to persons who may have used affected gift cards to purchase songs from the iTunes® Store.

You can find out how to make an Apple iTunes lawsuit claim here.

Ok—That’s enough for this week. See you at the bar—don’t forget your iPod.

Week Adjourned: 6.12.09

Top Class Actions

Miss-Match.com? The Dallas-based internet dating site Match.com is being sued over allegations that it misleads its customers about potential matches with people who are no longer active members.

The suit was filed by Sean McGinn, a resident of Brooklyn, NY, who alleges that most of the profiles on the site are for people who have cancelled their memberships or never subscribed. The complaint reportedly states “When a subscriber cancels their subscription, their profile continues to appear to be that of an active subscriber.” And, “Nothing indicates to the viewer their limited access to read e-mails or respond to them.” Ouch—kinda like the cyber version of a blind date who doesn’t show…

Pages: 12

Week Adjourned: 6.5.09

Top Class Actions

Ask for Generic? Mmmaybe not. Sometimes it’s best to skip the generic version—and such may be the case with Budeprion XL, a generic formulation of the antidepressant Wellbutrin XL; the makers of Budeprion XL are the subject of a class action lawsuit filed this week in California. The problem seems to be that the generic form of the drug is not as effective and possibly not as safe as the patented version, so the suit alleges. The FDA has so far said the drug is safe, but they could order a special clinical trial to better assess the safety and efficacy of the generic version.

Top Settlements

“Expedia-dot-CON?” Maybe that’s how the jingle should go after the recent judgement against the internet travel site. Unhappy customers who joined a class action lawsuit alleging breach of contract will see the travel giant fork over $184 million in settlement monies. What did they do? Expedia bundled the service-fee charges with taxes into a single line item, failing to disclose the separate amounts of each to consumers. Because Expedia only remits taxes based on the wholesale price—which it never disclosed to consumers—the taxes appear higher to consumers than they actually are, and Expedia is able to mask the considerable size of its service fees. Nice.

Pages: 12

Week Adjourned: 5.15.09

Top Class Actions: The Week of the Biggies

Hotel Costco: You can clock in, but you can never leave? It appears to have been another busy week in law firms and courthouses across North America. Let’s start with Costco—last week Costco was in the news for having settled an unfair business practices class action and this week they’re in the news for “falsely imprisoning” employees in its California warehouses. Whaaat?

When I first read this my mind reeled, “what new business venture is this?”

Turns out it’s yet another unpaid overtime and wages class action centered in California. What is it about California? (I’m referring to the endless labor law violations).

The class action centers on employees who were and are forced to remain in the warehouses after closing while store managers make goods secure and lock up. This has been going on for years, apparently. But now there is a lawsuit, of course, and the lawyers are seeking US $50 million in damages.

O Canada!—who was standing on guard at Guidant? Across the border in Canada, not a land well-known for class action lawsuits—something large is taking place. Earlier this month a national class action was certified against Guidant Corp, alleging that the company knowingly sold defective pacemakers. The class so far represents more than 28,000 people, and the lawyers are seeking CD$525 million in damages.

Highway Robbery? And a class action that’s been getting a lot of media this week is the Massachusetts Turnpike lawsuit, whose plaintiffs are being represented by a lawyer made famous in the 1998 film “A Civil Action“, Jan R. Schlichtmann.

Continue reading “Week Adjourned: 5.15.09”